Seeking Alpha

Creative Medical Technology Holdings Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ ("CELZ-201-DDT") Novel Cell Therapy to ...

Company reaches next clinical trial milestone for the intramuscular treatment of Chronic Lower Back Pain with the first novel allogenic cellular therapy in the United States PHOENIX, Oct. 10, 2023 ...
Seeking Alpha

Creative Medical Technology Holdings Secures FDA Fast Track Designation for CELZ-201-DDT - Advancing Breakthrough Therapy for Chronic Lower Back Pain

PHOENIX, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (CELZ), a clinical-stage biotechnology company focused on regenerative and immune cellular therapies, today ...
Nasdaq

Creative Medical Technology Holdings Issues Letter to Shareholders

2025 has been a landmark year for Creative Medical. With the support of the most comprehensive clinical, intellectual, and technological foundation in our Company’s history, we have evolved from proof ...